
#Investors:
Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We remain on track to deliver our full year guidance.
Press release: go.novartis.social/4cCsrje
IR Webcast: go.novartis.social/4cL7uBm
#NVSQ126 $NVS $NOVN
English























